News | Stents Drug Eluting | October 10, 2023

Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk

Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The data compare DESyne BDS Plus, the world’s first triple drug-eluting stent with local anticoagulation delivery technology using two anticoagulants (rivaroxaban and argatroban) and an anti-proliferative mTOR inhibitor (sirolimus) to a second-generation durable polymer DES.

“Stent thrombosis after percutaneous coronary intervention (PCI), though rare, is a severe complication with death or heart attack risk of up to 50% after the event. Dual antiplatelet therapy (DAPT) has played an integral role in keeping stent thrombosis rates low, but requires patient compliance for a minimum of six months and is associated with an increased risk of major bleeding,” said Motasim Sirhan, CEO of Elixir Medical. “DESyne BDS Plus with local anticoagulation delivery technology was designed to help mitigate the variable of drug compliance and to simplify the tradeoff decision of balancing the ischemic and bleeding risk. We are pleased to share the exciting findings from the first trial of DESyne BDS Plus as our team continues to innovate in the PCI space with our multiple platforms of disruptive technologies.”

The DESyne BDS Plus RCT includes 202 patients across 14 sites in Europe, New Zealand and Brazil. An imaging subset of 60 patients had angiographic and optical coherence tomography (OCT) assessment completed at six months. Data collection will continue through three years.

The data will be presented in the session “TCT Innovation V: Innovation in Coronary Disease Diagnosis and Therapies” on October 25th from 8-9:30 AM PDT in the Innovation & Clinical Science Theater, Hall B at the Moscone Center.

Elixir Medical is also hosting the scientific symposium, “Innovation for PCI: Improved outcomes require disruption” featuring a panel of speakers including Robert W. Yeh, M.D., Mirvat Alasnag, M.D, Ignacio Cruz-Gonzalez, M.D., Ph.D., Roxana Mehran, M.D. and Stefan Verheye, M.D., Ph.D.

The Elixir team will also exhibit at booth 115.

Full list of presentation details:

Innovation session: TCT Innovation V: Innovation in Coronary Disease Diagnosis and Therapies
Title: A Randomized Clinical Trial of a Novel Triple Drug Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus: Six-Month Clinical and Imaging Results of the DESyne BDS Plus Study
Presenter: Stefan Verheye, M.D., Ph.D.
Date: Wednesday, October 25, 2023
Time: 8:00 AM - 9:30 AM PDT
Location: Innovation & Clinical Science Theater, Hall B

Scientific symposium
Title: Innovation for PCI: Improved Outcomes Require Disruption
Presenters: Robert W. Yeh, M.D., Mirvat Alasnag, M.D., Ignacio Cruz-Gonzalez, M.D., Ph.D., Roxana Mehran, M.D. and Stefan Verheye, M.D., Ph.D.
Date: Tuesday, October 24, 2023
Time: 12:30 PM PDT
Location: Presentation Theater 3, Room 215, Level 2

Spotlight session: Coronary Spotlight 5: Disruptive Stent Technologies
Title: DynamX Coronary Bioadaptor Technology
Presenter: David Erlinge, M.D., Ph.D.
Date: Tuesday, October 24, 2023
Time: 3:30 PM - 4:55 PM PDT
Location: Coronary Spotlight Theater, Hall E, Exhibition Level

Spotlight session: Coronary Spotlight 5: Disruptive Stent Technologies
Title: DESyne BDS Plus Stent
Presenter: Stefan Verheye, M.D., Ph.D.
Date: Tuesday, October 24, 2023
Time: 3:30 PM - 4:55 PM PDT
Location: Coronary Spotlight Theater, Hall E, Exhibition Level

Session: Vulnerable Plaque Studies
Title: Plaque Stabilization and Regression: Another Significant Benefit of DynamX Bioadaptor
Presenter: Stefan Verheye, M.D., Ph.D.
Date: Wednesday, October 25, 2023
Time: 10:00 AM - 10:54 AM PDT
Location: Moderated Abstracts Station 8 – Emerging Clinical Science & Research Sessions, Hall C, Exhibition Level

Session: BVS Studies II
Title: 12-Month Clinical Outcomes of Patients Treated with the Novel DynamX Bioadaptor: DynamX Hong Kong Registry
Presenter: Wai Kin Chi, M.D.
Date: October 25, 2023
Time: 11:00 AM - 12:03 PM PDT
Location: Moderated Abstracts Station 6 – Emerging Clinical Science & Research, Hall C, Exhibition Level

Session: BVS Studies II
Title: Positive Adaptive Remodeling Effect of the DynamX Bioadaptor in BIOADAPTOR RCT
Presenter: Mark Webster, M.D.
Date: October 25, 2023
Time: 11:00 AM - 12:03 PM PDT
Location: Moderated Abstracts Station 6 – Emerging Clinical Science & Research, Hall C, Exhibition Level

For more information: www.elixirmedical.com

Find more TCT23 conference coverage here

Related TCT Coverage: 

CRF Announces TCT 2023 Late-breaking Clinical Trials

VIDEO: Precision Cardiovascular Medicine: The Next Frontier in Patient Care and Innovation 

VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial 

VIDEO: Unique Features of Coronary Artery Disease in Women 

Cardiovascular Research Foundation’s (CRF) TCT 2022 in Review 

Photo Gallery Highlighting TCT 2022 

Cardiovascular Research Foundation’s (CRF) TCT 2022 in Review 

TCT 2022 Honors Recipient of Thomas J. Linnemeier Young Investigator Award 

TCT 2022 Announces Winner of Shark Tank Innovation Award 

Educational Leaders Join Forces on Educational Opportunities 

Top TCT 2022 Award Recipients announced by Cardiovascular Research Foundation (CRF) 


Related Content

News | TCT

Oct. 11, 2024 – As the pace of change accelerates in healthcare, the most pressing questions in cardiovascular medicine ...

Home October 16, 2024
Home
News | TCT

November 9, 2023 — Medinbox, a global provider of video integrated collaboration systems for interventional rooms and ...

Home November 09, 2023
Home
News | TCT

October 30, 2023 — Shockwave Medical, Inc., which develops technologies for the treatment of cardiovascular disease, has ...

Home October 30, 2023
Home
News | TCT

October 26, 2023 — The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued ...

Home October 26, 2023
Home
News | TCT

October 26, 2023 — A new study presented at TCT 2023 revealed inequities in access to mechanical circulatory support in ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Elixir Medical, developer of novel cardiovascular technologies, announced positive six-month clinical ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Medtronic plc, a global leader in healthcare technology, announced four-year results from the Evolut ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — Information on a new double lumen catheter was presented by Nabil Dib, MD, MSc, FACC, FESC, during ...

Home October 25, 2023
Home
News | TCT

October 25, 2023 — For its novel multi-lumen stent system for interventional adjustment of pulmonary blood flow in ...

Home October 25, 2023
Home
Feature | TCT | By Melinda Taschetta-Millane

Innovation. Connection. Inspiration. The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference, the ...

Home October 20, 2023
Home
Subscribe Now